Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 2 | BMC Cancer

Figure 2

From: Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden

Figure 2

Increased expressions of CSC and embryonic stem cell markers in ascites- derived tumor cells in response to paclitaxel. Expression and localisation of EpCAM, CD117, Oct4 and NANOG in ascites-derived tumor cells in response to paclitaxel treatment was evaluated by immunofluorescence as described in Figure 1. Images are representative of three independent experiments from three independent patient ascites samples. The mean fluorescence intensity of CSC markers CD117, EpCAM and the embryonic stem cell markers NANOG and Oct4 expression in ascites-derived tumor cells was quantified using Cell-R software. Significant variations between the groups are indicated by *P < 0.05. Magnification 200×; scale bar = 10 μM.

Back to article page